Effect of Ivabradine in Stage D HF/Cardiogenic Shock Patients on Dobutamine

Inclusion Criteria: * Provide written informed consent for the study * Have current diagnosis of Ischemic and/or non-ischemic cardiomyopathy * Left ventricular ejection fraction (LVEF) \< 30% by echo during the screening * Sinus rhythm with HR ≥100 bpm * Systolic blood pressure ≥ 90 mmHg assessed by cuff sphygmomanometer * CI \< 2.2 L/min/m2 * Current symptom(s) of HF (New York Heart Association (NYHA) class IV) at Screening. * Absence of hypovolemia, defined as a central venous pressure ≥10 mmHg and pulmonary capillary occlusion pressure ≥15 mmHg before administration of Dobutamine Exclusion Criteria: * Respiratory support with mechanical ventilation * Circulatory mechanical support * Atrial pacing with the presence of sick sinus syndrome or sino-atrial block * Second or third degree atrioventricular (AV) block, * Atrial fibrillation/flutter * Amiodarone treatment * Ventricular tachycardia * Acute coronary syndrome * Bilirubin \> 2.5 * Alanine aminotransferase (ALT) \>60 IE/L, * Serum creatinine \>2.5 g/ml) * Fever and significant infection * Pregnancy * Anemia, Hgb \< 9.0 * Patients required treated with severe cytochrome CYP3A4 inhibitors drugs Concomitant use of strong CYP3A4 inhibitors will be avoided during the study period